Hospira Inc. (NYSE:HSP), based in Lake Forest, Illinois, is the world’s leading provider of injectable drugs and infusion technologies and a global leader in biosimilars. On February 5, 2015, the company received a $90 per share cash merger offer from Pfizer Inc., valuing Hospira at $15.2 billion. The transaction closed on September 3, 2015, following shareholder and regulatory approvals, and the deal created a leading global injectables business. The Fund earned an annualized return of 5.82%.
From Mario Gabelli (Trades, Portfolio)'s ABC Fund third quarter commentary.
